Exploring the Effects of Brentuximab Vedotin on Cancer Cells
Brentuximab Vedotin works by targeting and binding to a protein known as CD30 on cancer cells.
Brentuximab Vedotin works by targeting and binding to a protein known as CD30 on cancer cells.
Trastuzumab emtansine (T-DM1) is a combination of the chemotherapy drug called emtansine and the monoclonal antibody trastuzumab.
CD30 is expressed in some tumor cells, making it a potential target for cancer immunotherapy.
In normal cells, HER2 helps to regulate cell growth and division. However, in HER2-positive breast cancer, the cells produce too much of this protein.
Antibody-drug conjugates (ADCs) are therapeutic agents that consist of monoclonal antibodies that are linked to a small-molecule drug or a cytotoxic...
Whether you're a CRO making customer deliveries, a start-up advancing towards IND, or an established biopharma supporting multiple programs at once, Affinity supports every team, at every step, on a single platform, for a single price.